Moderna
RSV
page 2 of 3
4C
(near RSV)
Adverse Reactions
In a clinical trial conducted in participants 60 
years of age and older, the most commonly 
reported (≥10%) adverse reactions were injection-
site pain (55.9%), fatigue (30.8%), headache 
(26.7%), myalgia (25.6%), arthralgia (21.7%), axillary 
(underarm) swelling or tenderness (15.2%) and 
chills (11.6%). 
In a clinical trial conducted in participants 18 
through 59 years of age at increased risk for LRTD 
caused by RSV, the most commonly reported 
(≥10%) adverse reactions were injection site  
pain (73.9%), fatigue (36.9%), headache (33.3%), 
myalgia (28.9%), arthralgia (22.7%), chills (19.9%), 
axillary (underarm) swelling or tenderness (17.1%), 
and nausea/vomiting (10.8%).
To report suspected adverse reactions, contact 
ModernaTX, Inc. at 1-866-663-3762  
or VAERS at 1-800-822-7967 or  
www.vaers.hhs.gov. 
Please see the Brief Summary of the mRESVIA 
Full Prescribing Information on the following 
page. 
Scan to learn more  
about mRESVIA.
LRTD = lower respiratory tract disease; RSV = respiratory syncytial virus. 
References: 1. mRESVIA Prescribing Information. ModernaTX, Inc. 2. Britton A, 
Roper LE, Kotton CN, et al. Use of respiratory syncytial virus vaccines in adults 
aged ≥60 years: updated recommendations of the Advisory Committee on 
Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 
2024;73(32):696-702. doi:10.15585/mmwr.mm7332e1 
Colorado & Connecticut prescribers and pharmacists may view WAC 
information at modernadirect.com/wac-disclosure
© 2026 Moderna  US-RSV-2400109  04/2026

View this content as a flipbook by clicking here.